Oestrogen receptor β ligand acts on CD11c+ cells to mediate protection in experimental autoimmune encephalomyelitis
Open Access
- 8 December 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 141 (1) , 132-147
Abstract
Oestrogen treatments are neuroprotective in a variety of neurodegenerative disease models. Selective oestrogen receptor modifiers are needed to optimize beneficial effects while minimizing adverse effects to achieve neuroprotection in chronic diseases. Oestrogen receptor beta (ERβ) ligands are potential candidates. In the multiple sclerosis model chronic experimental autoimmune encephalomyelitis, ERβ-ligand treatment is neuroprotective, but mechanisms underlying this neuroprotection remain unclear. Specifically, whether there are direct effects of ERβ-ligand on CD11c+ microglia, myeloid dendritic cells or macrophages in vivo during disease is unknown. Here, we generated mice with ERβ deleted from CD11c+ cells to show direct effects of ERβ-ligand treatment in vivo on these cells to mediate neuroprotection during experimental autoimmune encephalomyelitis. Further, we use bone marrow chimeras to show that ERβ in peripherally derived myeloid cells, not resident microglia, are the CD11c+ cells mediating this protection. CD11c+ dendritic cell and macrophages isolated from the central nervous system of wild-type experimental autoimmune encephalomyelitis mice treated with ERβ-ligand expressed less iNOS and T-bet, but more IL-10, and this treatment effect was lost in mice with specific deletion of ERβ in CD11c+ cells. Also, we extend previous reports of ERβ-ligand’s ability to enhance remyelination through a direct effect on oligodendrocytes by showing that the immunomodulatory effect of ERβ-ligand acting on CD11c+ cells is necessary to permit the maturation of oligodendrocytes. Together these results demonstrate that targeting ERβ signalling pathways in CD11c+ myeloid cells is a novel strategy for regulation of the innate immune system in neurodegenerative diseases. To our knowledge, this is the first report showing how direct effects of a candidate neuroprotective treatment on two distinct cell lineages (bone marrow derived myeloid cells and oligodendrocytes) can have complementary neuroprotective effects in vivo.Keywords
Funding Information
- NIH (R01NS096748)
- Conrad N. Hilton Foundation (#20150232)
- California Community Foundation (#BAPP-15-118094)
This publication has 67 references indexed in Scilit:
- A high throughput drug screening assay to identify compounds that promote oligodendrocyte differentiation using acutely dissociated and purified oligodendrocyte precursor cellsBMC Research Notes, 2016
- Estrogen receptor β and Liver X receptor β: biology and therapeutic potential in CNS diseasesMolecular Psychiatry, 2014
- AC-186, a Selective Nonsteroidal Estrogen Receptor β Agonist, Shows Gender Specific Neuroprotection in a Parkinson’s Disease Rat ModelACS Chemical Neuroscience, 2013
- Estrogen Receptor α Signaling in T Lymphocytes Is Required for Estradiol-Mediated Inhibition of Th1 and Th17 Cell Differentiation and Protection against Experimental Autoimmune EncephalomyelitisThe Journal of Immunology, 2011
- Estrogen receptor‐β ligand treatment modulates dendritic cells in the target organ during autoimmune demyelinating diseaseEuropean Journal of Immunology, 2010
- Treatment with an Estrogen Receptor Ligand Is Neuroprotective in Experimental Autoimmune EncephalomyelitisJournal of Neuroscience, 2006
- Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosisNature Medicine, 2005
- Response-Specific and Ligand Dose-Dependent Modulation of Estrogen Receptor (ER) α Activity by ERβ in the UterusEndocrinology, 2003
- Characterization of the Biological Roles of the Estrogen Receptors, ERα and ERβ, in Estrogen Target Tissuesin Vivothrough the Use of an ERα-Selective LigandEndocrinology, 2002
- Estriol ameliorates autoimmune demyelinating diseaseNeurology, 1999